Goldman Sachs has initiated coverage on Danaher Corp (DHR) with a Buy rating as of December 8, 2025. This marks the firm's first evaluation of the company's investment potential based on extensive research of its business and industry dynamics.
Danaher Corp operates within the Life Sciences Tools & Services sector, focusing on the design, manufacture, and marketing of medical and commercial products. Headquartered in Washington, D.C., the company employs approximately 61,000 people and is structured into three segments: Biotechnology, Life Sciences, and Diagnostics.
As of December 4, 2025, Danaher boasts a market capitalization of $160.8 billion, a P/E ratio of 45.91, and an EPS of 4.86. The company has a dividend yield of 56.0%. Upcoming earnings reports are scheduled for April 20, 2026, with an EPS estimate of $2.02, and July 20, 2026, with an EPS estimate of $1.98.
Analyst ratings are based on professional assessments that consider various factors, including company fundamentals and industry trends. The current consensus among analysts is a Buy, with 12 Strong Buy, 13 Buy, and 4 Hold ratings.
Such decisions reflect the evolving landscape of analyst opinions, which can change as new information becomes available. Investors should view these ratings as one of many factors in their decision-making process.